ERBB2 and breast carcinoma: This was observed in both breast cancer and GBM datasets and leaves open the possibility that selection of well-known drivers such as ERBB2 and EGFR may be synergistically acting on altered metabolic processes abrogated by co-altered, nearby metabolism genes.